Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Since 2015, the Chinese government has introduced numerous reforms with the aim of establishing a more scientific and efficient drug regulatory system, which are highlighted here.
The market for hepatocellular carcinoma is set to change with the recent approvals of the kinase inhibitor lenvatinib and the immune checkpoint inhibitor nivolumab, as well as the anticipated approvals of further immunotherapies.
This analysis highlights data indicating the limitations of traditional clinical trial processes, and discusses how moving clinical trials into large clinical care settings could help meet the growing demands for large volumes of sophisticated patient data.
This article discusses the market for oral anticoagulants, and how therapies in development and antidotes to existing drugs could affect the therapeutic landscape.
How many cancer cell therapies are being developed? To harmonize efforts in this arena, the Cancer Research Institute has curated a database that includes all cell therapies in development.
This article discusses the market for therapies for haemophila, which is forecast to change substantially with the recent launch of emicizumab and the potential future approvals of gene therapies and non-factor treatments.
This article highlights results from a comprehensive study of the performance of clinical trial sites, which could help companies understand the underlying drivers of success.
